OBJECTIVE: Mantle cell lymphoma (MCL) is a lymphoma characterized by aberrant activation of CCND1/cyclin D1 followed by sequential genetic abnormalities. Genomic abnormalities in MCL have been extensively examined by classical cytogenetics and microarray-based comparative genomic hybridization techniques, pointing out a number of alterations in genomic regions that correlate with the neoplastic phenotype and survival. Recently, single nucleotide polymorphism genomic microarrays (SNP-chip) have been developed and used for analysis of cancer genomics. This technique allows detection of genomic changes with higher resolution, including loss of heterozygosity without changes of gene dosage, so-called acquired uniparental disomy (aUPD). MATERIALS AND METHODS: We have examined 33 samples of MCL (28 primary MCL and 5 cell lines) using the 250,000 SNP-chip from Affymetrix. RESULTS: Known alterations were confirmed by SNP arrays, including deletion of INK4A/ARF, duplication/amplification of MYC, deletion of ATM, and deletion of TP53. We also identified a duplication/amplification that occurred at 13q involving oncogenic microRNA, miR17-92. We found other genomic abnormalities, including duplication/amplification of cyclin D1, del(1p), del(6q), dup(3q) and dup(18q). Our SNP-chip analysis detected these abnormalities at high resolution, allowing us to narrow the size of the commonly deleted regions, including 1p and 6q. Our SNP-chip analysis detected a number of aUPD sites, including whole chromosome 9 aUPD and 9p aUPD. We also found an MCL case with 19p, leading to homozygous deletion of TNFSF genes. CONCLUSION: SNP-chip analysis detected in MCL very small genomic gains/losses, as well as aUPDs, which could not be detected by more conventional methods.
OBJECTIVE:Mantle cell lymphoma (MCL) is a lymphoma characterized by aberrant activation of CCND1/cyclin D1 followed by sequential genetic abnormalities. Genomic abnormalities in MCL have been extensively examined by classical cytogenetics and microarray-based comparative genomic hybridization techniques, pointing out a number of alterations in genomic regions that correlate with the neoplastic phenotype and survival. Recently, single nucleotide polymorphism genomic microarrays (SNP-chip) have been developed and used for analysis of cancer genomics. This technique allows detection of genomic changes with higher resolution, including loss of heterozygosity without changes of gene dosage, so-called acquired uniparental disomy (aUPD). MATERIALS AND METHODS: We have examined 33 samples of MCL (28 primary MCL and 5 cell lines) using the 250,000 SNP-chip from Affymetrix. RESULTS: Known alterations were confirmed by SNP arrays, including deletion of INK4A/ARF, duplication/amplification of MYC, deletion of ATM, and deletion of TP53. We also identified a duplication/amplification that occurred at 13q involving oncogenic microRNA, miR17-92. We found other genomic abnormalities, including duplication/amplification of cyclin D1, del(1p), del(6q), dup(3q) and dup(18q). Our SNP-chip analysis detected these abnormalities at high resolution, allowing us to narrow the size of the commonly deleted regions, including 1p and 6q. Our SNP-chip analysis detected a number of aUPD sites, including whole chromosome 9 aUPD and 9p aUPD. We also found an MCL case with 19p, leading to homozygous deletion of TNFSF genes. CONCLUSION: SNP-chip analysis detected in MCL very small genomic gains/losses, as well as aUPDs, which could not be detected by more conventional methods.
Authors: Holger Kohlhammer; Carsten Schwaenen; Swen Wessendorf; Karlheinz Holzmann; Hans A Kestler; Dirk Kienle; Thomas F E Barth; Peter Möller; German Ott; Jörg Kalla; Bernhard Radlwimmer; Armin Pscherer; Stephan Stilgenbauer; Hartmut Döhner; Peter Lichter; Martin Bentz Journal: Blood Date: 2004-04-13 Impact factor: 22.113
Authors: Irene M Ghobrial; Daniel J McCormick; Scott H Kaufmann; Alexey A Leontovich; David A Loegering; Nga T Dai; Kelly L Krajnik; Mary J Stenson; Mona F Melhem; Anne J Novak; Stephen M Ansell; Thomas E Witzig Journal: Blood Date: 2005-01-13 Impact factor: 22.113
Authors: Alicja M Gruszka-Westwood; Shayne Atkinson; Brenda M Summersgill; Janet Shipley; Manal O Elnenaei; Paresh Jain; Rifat A Hamoudi; Jaspal S Kaeda; Andrew C Wotherspoon; Estella Matutes; Daniel Catovsky Journal: Genes Chromosomes Cancer Date: 2002-02 Impact factor: 5.006
Authors: Margit Schraders; Rolph Pfundt; Huub M P Straatman; Irene M Janssen; Ad Geurts van Kessel; Eric F P M Schoenmakers; Johan H J M van Krieken; Patricia J T A Groenen Journal: Blood Date: 2004-10-21 Impact factor: 22.113
Authors: D Grosso; E Johnson; B Colombe; O Alpdogan; M Carabasi; J Filicko-O'Hara; S Gaballa; M Kasner; T Klumpp; U Martinez-Outschoorn; J L Wagner; M Weiss; Z Wang; N Flomenberg Journal: Bone Marrow Transplant Date: 2017-01-09 Impact factor: 5.483
Authors: Elena M Hartmann; Elias Campo; George Wright; Georg Lenz; Itziar Salaverria; Pedro Jares; Wenming Xiao; Rita M Braziel; Lisa M Rimsza; Wing-Chung Chan; Dennis D Weisenburger; Jan Delabie; Elaine S Jaffe; Randy D Gascoyne; Sandeep S Dave; Hans-Konrad Mueller-Hermelink; Louis M Staudt; German Ott; Sílvia Beà; Andreas Rosenwald Journal: Blood Date: 2010-04-26 Impact factor: 22.113
Authors: Raj Chari; Kelsie L Thu; Ian M Wilson; William W Lockwood; Kim M Lonergan; Bradley P Coe; Chad A Malloff; Adi F Gazdar; Stephen Lam; Cathie Garnis; Calum E MacAulay; Carlos E Alvarez; Wan L Lam Journal: Cancer Metastasis Rev Date: 2010-03 Impact factor: 9.264
Authors: Marcus Høy Hansen; Karen Juul-Jensen; Oriane Cédile; Stephanie Kavan; Michael Boe Møller; Jacob Haaber; Charlotte Guldborg Nyvold Journal: Leuk Res Rep Date: 2021-06-01